Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-02-01 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：向特定对象发行限售股上市流通公告
Share Issue/Capital Change Classification · 100% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding the listing and circulation of restricted shares issued to specific investors. It details the number of shares, the lock-up period, the shareholders involved, and the regulatory approvals received. The document does not contain financial statements or detailed financial analysis but focuses on the share issuance and listing event. The document length is 2681 characters, which is relatively short and consistent with an announcement rather than a full report. The content matches the description of a Share Issue/Capital Change announcement, specifically about restricted shares becoming freely tradable and listed. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2024-02-01 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司向特定对象发行限售股上市流通的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from a sponsoring securities company regarding the listing and circulation of restricted shares issued to specific investors by Shanghai Medicilon Inc. It details the number of shares, lock-up periods, shareholder commitments, and compliance with relevant securities laws and stock exchange rules. The document is a formal verification or audit opinion on the issuance and circulation of restricted shares, not a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on compliance and verification of share issuance and circulation. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and verification opinions related to regulatory compliance and share issuance. Q1 2024
2024-02-01 Chinese
美迪西：关于推动公司“提质增效重回报”及以集中竞价交易方式回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the progress of its share repurchase program through centralized bidding transactions. It details the number of shares repurchased, prices, total funds used, and the company's intentions and governance measures related to the buyback. The document references regulatory compliance and previous announcements about the buyback plan. It does not contain financial statements or detailed financial performance data but focuses on the update of the share repurchase activity. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares.
2024-01-31 Chinese
美迪西：2023年年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast (业绩预告) from Shanghai Medicilon Inc., providing preliminary estimated net profit and net profit excluding non-recurring items for the full year 2023. It explicitly states that the forecast is unaudited and preliminary, with final audited results to be disclosed in the formal 2023 annual report. The document length is short (1407 characters) and it does not contain actual audited financial statements or detailed financial analysis, only forecasted figures and explanations. This type of document is a performance forecast or earnings guidance, which is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a fiscal period before the full report is published. It is not the full Annual Report (10-K), nor an Interim Report (IR), nor a Report Publication Announcement (RPA) since it contains substantive financial forecast data rather than just a notice of report availability. Therefore, the best fitting classification is Earnings Release (ER). FY 2023
2024-01-30 Chinese
美迪西：关于股东部分股份解除质押的公告
Transaction in Own Shares Classification · 95% confidence The document is a short announcement (708 characters) about a shareholder, Chen Guoxing, releasing a partial pledge of shares in the company Shanghai Medicilon Inc. It details the number of shares released from pledge, the percentage of total shares, and confirms no remaining pledged shares. There is no financial data, no report attached or referenced, and it is clearly about a transaction involving shares owned by a director or shareholder. This fits the definition of a Transaction in Own Shares (POS) filing, which covers share repurchase or issuance activities, including pledge or release of pledged shares by insiders or shareholders.
2024-01-26 Chinese
美迪西：关于实际控制人增加一致行动人及一致行动人之间内部转让股份计划的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by Shanghai Medicilon Inc. regarding an internal share transfer plan between the company's actual controller and a related party (father and son). It details the transfer of shares within consistent action parties, clarifies that the total shareholding remains unchanged, and emphasizes compliance with relevant stock exchange rules. The document does not contain financial statements, audit results, or detailed financial performance data. It is not a report but an announcement about a shareholding change within controlling parties. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels, especially involving consistent action parties and internal transfers. The document length is 2821 characters, which is typical for such announcements. Therefore, the correct classification is MRQ with high confidence.
2024-01-12 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.